Paul Shaughnessy, MD

Director of the Sarah Cannon Transplant and Cellular Therapy Program

Methodist Hospital in San Antonio, Texas

Published Articles (1)

CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next

July 17, 2026

Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.